Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus MOXAM.
FACTIVE vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic